

ALLIA.143A



PAV 1806
PATENT 1642
8-21-98
#14

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Habib Zaghouani) Group Art Unit 1806
Serial No. : 08/779,767)
Filed : January 7, 1997)
For : Compounds, Compositions, and)
Methods For The Endocytic)
Presentation of Immunosuppressive)
Factors)
Examiner : J. Reeves)

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on

July 15, 1998

Christopher A. Dayton
Christopher A. Dayton, Reg. No. 35,114

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Enclosed is form PTO-1449 listing references that are also enclosed. This Information Disclosure Statement is being filed before the mailing date of a final office action under 37 C.F.R. § 1.113 and before the mailing date of a notice of allowance under Section 1.311. A certification under 37 C.F.R. §1.97 (e) (2) is set forth below. Thus, no fee is required as set forth in 37 C.F.R. §1.97 (c).

The undersigned certifies that each item of information contained within this Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement.

RECEIVED

JUL 23 1998

MAIL ROOM
SERVICE CENTER


Serial No. : 08/779,767
Filed : January 7, 1997

Applicants respectfully solicit the Examiner's consideration of the cited references and entry thereof into the record of this application.

Respectfully submitted,

ALLIANCE PHARMACEUTICAL CORP.

Dated: 15 July 1998

By: 
Christopher A. Dayton
Registration No. 35,114
Attorney of Record

143sup.doc